The Mecp2-NR axis, particularly the regulation of NRs by Mecp2 during quiescence exit, presents a potential therapeutic target for enhancing tissue regeneration or suppressing uncontrolled cell proliferation in disease conditions. By modulating the expression or activity of specific NRs, such as Rara and Nr1h3, it may be possible to fine-tune the balance between metabolism and proliferation in cells undergoing quiescence exit. Targeting this axis could help promote controlled cell proliferation during tissue regeneration or inhibit excessive proliferation in conditions like cancer. Further research into the specific mechanisms and downstream effects of targeting the Mecp2-NR axis is needed to explore its therapeutic potential in various disease contexts.